PREVIOUSLY TREATED AMYLOID LIGHT-CHAIN (AL) AMYLOIDOSIS

Clinical trials for PREVIOUSLY TREATED AMYLOID LIGHT-CHAIN (AL) AMYLOIDOSIS explained in plain language.

Never miss a new study

Get alerted when new PREVIOUSLY TREATED AMYLOID LIGHT-CHAIN (AL) AMYLOIDOSIS trials appear

Sign up with your email to follow new studies for PREVIOUSLY TREATED AMYLOID LIGHT-CHAIN (AL) AMYLOIDOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

First patients receive experimental Triple-Action drug for Tough-to-Treat blood cancers

Disease control Recruiting now

This is the first time researchers are testing a new experimental drug called JNJ-79635322 in people. The main goal is to find a safe dose for future studies. The trial is for adults with advanced multiple myeloma or AL amyloidosis, two serious blood disorders, who have already t…

Matched conditions: PREVIOUSLY TREATED AMYLOID LIGHT-CHAIN (AL) AMYLOIDOSIS

Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control

Last updated Mar 30, 2026 14:32 UTC

PREVIOUSLY TREATED AMYLOID LIGHT-CHAIN (AL) AMYLOIDOSIS

Get alerted when new PREVIOUSLY TREATED AMYLOID LIGHT-CHAIN (AL) AMYLOIDOSIS trials appear

First patients receive experimental Triple-Action drug for Tough-to-Treat blood cancers